Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Year End 2021 Financial Results and Business Update

Rhea-AI Summary

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) will report its fourth quarter and year-end 2021 financial results on March 1, 2022, after market close. A live conference call and webcast will follow at 4:30 PM ET for management to discuss the results and provide business updates. Rigel, known for its TAVALISSE product, focuses on developing drugs for hematologic disorders and rare diseases. The company is also conducting various clinical trials for treatments in autoimmune and COVID-19-related conditions.

Positive

• Upcoming announcement of Q4 and year-end 2021 financial results may provide insights into company performance.
• Rigel holds a promising position in developing small molecule drugs for hematologic disorders and COVID-19.

Negative

• No specific financial metrics or results are mentioned in the PR, creating uncertainty regarding company performance.

SOUTH SAN FRANCISCO, Calif., Feb. 22, 2022 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its fourth quarter and year end 2021 financial results after market close on Tuesday, March 1, 2022. Rigel senior management will follow the announcement with a live conference call and webcast at 4:30pm Eastern Time (1:30pm Pacific Time) to discuss the financial results and give an update on the business.

Participants can access the live conference call by dialing 877-407-3088 (domestic) or 201-389-0927 (international). The conference call and accompanying slides will also be webcast live and can be accessed from the Investor Relations section of the company's website at www.rigel.com. The webcast will be archived and available for replay for 90 days after the call via the Rigel website.

About Rigel
Rigel Pharmaceuticals, Inc., is a biotechnology company dedicated to developing and commercializing novel small molecule drugs that significantly improve the lives of patients with hematologic disorders, cancer, and rare immune diseases. Rigel's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE^® (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The product is also commercially available in Europe (TAVLESSE), the United Kingdom, and Canada (TAVALISSE) for the treatment of chronic immune thrombocytopenia in adult patients. 

Fostamatinib is currently being studied in a Phase 3 clinical trial (NCT03764618) for the treatment of warm autoimmune hemolytic anemia (wAIHA)¹; a Phase 3 clinical trial (NCT04629703) for the treatment of hospitalized high-risk patients with mild-to-moderate COVID-19¹; an NIH/NHLBI-funded Phase 3 ACTIV-4 Host Tissue Study (NCT04924660) for the treatment of COVID-19 in hospitalized patients on oxygen therapy, and a Phase 2 clinical trial (NCT04581954) for the treatment of COVID-19 being conducted by Imperial College London.

Rigel's other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program, and a receptor-interacting serine/threonine-protein kinase (RIPK1) inhibitor program in clinical development with partner Eli Lilly and Company. In addition, Rigel has product candidates in development with partners BerGenBio ASA and Daiichi Sankyo.

For further information, visit www.rigel.com or follow us on Twitter or LinkedIn. 

Please see www.TAVALISSE.com for the full Prescribing Information.

¹The product for this use or indication is investigational and has not been proven safe or effective by any regulatory authority.

Investor Contact:
Jodi Sievers
Rigel Pharmaceuticals, Inc.
Phone: 650.624.1232
Email: ir@rigel.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/rigel-announces-conference-call-and-webcast-to-report-fourth-quarter-and-year-end-2021-financial-results-and-business-update-301487049.html

SOURCE Rigel Pharmaceuticals, Inc.

FAQ

When will Rigel Pharmaceuticals report its Q4 2021 financial results?

Rigel Pharmaceuticals will report its Q4 2021 financial results on March 1, 2022.

What time is the Rigel Pharmaceuticals conference call?

The conference call will take place at 4:30 PM ET on March 1, 2022.

How can I access the Rigel Pharmaceuticals conference call?

You can access the conference call by dialing 877-407-3088 for domestic or 201-389-0927 for international participants.

What is TAVALISSE and is it available in other markets?

TAVALISSE is Rigel's FDA-approved oral SYK inhibitor for chronic immune thrombocytopenia, available in Europe, the UK, and Canada.

What clinical trials is Rigel Pharmaceuticals currently involved in?

Rigel is conducting several clinical trials, including studies for autoimmune hemolytic anemia and COVID-19 treatments.